BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kanat O, Ertas H, Caner B. Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status. World J Clin Cases 2018; 6(11): 418-425 [PMID: 30294606 DOI: 10.12998/wjcc.v6.i11.418]
URL: https://www.wjgnet.com/1948-5204/full/v6/i11/418.htm
Number Citing Articles
1
Immune Resistance and EGFR Antagonists in Colorectal CancerCancers 2019; 11(8): 1089 doi: 10.3390/cancers11081089
2
Michael P. Castro, Mohammad Afshar, Coralie Williams, Thomas Turcat, David Parker, Eva Gordon, Jessica Zambelli, Amber McDonald, Collen Suh, Sheley Baylon, Saskia Biskup. Utility of Serial Transcriptomic Analyses to Characterize the Resistome and to Refine Treatment Selection for Metastatic Colon Cancer: Case ReportClinical Colorectal Cancer 2021; 20(1): 96 doi: 10.1016/j.clcc.2020.10.003
3
Marissa Lam, Caroline Lum, Sarah Latham, Sam Tipping Smith, Hans Prenen, Eva Segelov. <p>Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects</p>Cancer Management and Research 2020; : 5819 doi: 10.2147/CMAR.S213236
4
A. A. Daks, O. A. Fedorova, O. Y. Shuvalov, S. E. Parfenev, N. A. Barlev. The Role of ERBB2/HER2 Tyrosine Kinase Receptor in the Regulation of Cell DeathBiochemistry (Moscow) 2020; 85(10): 1277 doi: 10.1134/S0006297920100156
5
Elaine S. Tan, Todd C. Knepper, Xuefeng Wang, Jennifer B. Permuth, Liang Wang, Jason B. Fleming, Hao Xie. Copy Number Alterations as Novel Biomarkers and Therapeutic Targets in Colorectal CancerCancers 2022; 14(9): 2223 doi: 10.3390/cancers14092223